Skip to content
Study details
Enrolling now

Processes and Circuitry Underlying Threat Sensitivity as a Treatment Target for Co-morbid Anxiety and Depression

Laureate Institute for Brain Research, Inc.
NCT IDNCT06004115ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

165

Study length

about 4.1 years

Ages

18–65

Locations

1 site in OK

What this study is about

This trial is testing whether the way people process threats in their brains differs between those with anxiety and depression, and how this affects their response to an anti-anxiety drug. It uses brain imaging to compare threat processing in individuals with comorbid anxiety and depression versus those with just depression or just anxiety.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Placebo
  • 2.Take Lorazepam

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

lorazepam

Drug routes

oral (Oral Tablet)

Body systems

Psychiatry / Mental Health